...
首页> 外文期刊>Oncology letters >Sequencing of circulating tumor DNA for dynamic monitoring of gene mutations in advanced non-small cell lung cancer
【24h】

Sequencing of circulating tumor DNA for dynamic monitoring of gene mutations in advanced non-small cell lung cancer

机译:循环肿瘤DNA对晚期非小细胞肺癌基因突变动态监测的测序

获取原文
获取原文并翻译 | 示例
           

摘要

Lung cancer is the most commonly occurring type of cancer worldwide and also has the highest mortality rate. Although targeted therapy of non-small cell lung carcinoma (NSCLC) has become common, the majority of patients receiving first-line epithelial growth factor receptor (EGFR)-TKI treatment develop drug resistance. The EGFR T790M (NM_005228.4(EGFR): c.2369C>T (p.Thr790Met)) mutation accounts for half of all reported resistance cases; however, the molecular mechanism resulting in the drug resistance remains to be characterized. Circulating tumor DNA (ctDNA) isolated from plasma has great potential for identification of gene mutations in NSCLC. Collection of ctDNA is relatively non-invasive and can avoid the inherent disadvantages of tissue biopsy. In the present study, next-generation sequencing technology was used to detect the variation of ctDNA in the peripheral blood of patients administered with EGFR-TKI. The patients were monitored serially to establish a dynamic resistance gene detection system, with the rationale being to alter the treatment strategy as soon as the emergence of drug resistance gene mutations. A mutation spectrum of the group of patients was constructed. A driver gene mutation was identified in the ctDNA of each patient, and certain patients had clinically targetable gene mutations like EGFR, ROS proto-oncogene receptor tyrosine kinase and B-Raf proto-oncogene serine/threonine kinase. The dynamic monitoring of EGFR status indicated that the EGFR mutation rate was consistent with the tumor burden of patients. Overall, ctDNA detection is a useful method for the molecular genotyping of patients with cancer. The dynamic resistance gene detection system described in the present study is a sensitive and useful tool for the monitoring of gene status, which has potential to be used for direction of treatment strategy by detecting the emergence of drug resistance gene mutations.
机译:肺癌是全世界最常见的癌症,也具有最高的死亡率。虽然针对非小细胞肺癌(NSCLC)的靶向治疗变得常见,但大多数患者接受一线上皮生长因子受体(EGFR)-TKI治疗产生耐药性。 EGFR T790M(NM_005228.4(EGFR):C.2369C> T(P.Thrh790met))突变占所有报告的阻力病例的一半;然而,导致耐药性的分子机制仍有待征性。从血浆中分离的循环肿瘤DNA(CTDNA)具有巨大的NSCLC中基因突变的潜力。 CTDNA的集合是相对无侵入性的,可以避免组织活检的固有缺点。在本研究中,使用下一代测序技术来检测患有EGFR-TKI的患者外周血中CTDNA的变异。促进患者以建立动态抗性基因检测系统,基本原理是在耐药基因突变的出现后立即改变治疗策略。构建了该组患者的突变谱。在每位患者的CTDNA中鉴定了驾驶员基因突变,并且某些患者具有临床上可靶向基因突变,如EGFR,ROS原癌基因受体酪氨酸激酶和B-RAF原胺丝氨酸/苏氨酸激酶。 EGFR状态的动态监测表明EGFR突变率与患者的肿瘤负担一致。总体而言,CTDNA检测是癌症患者分子基因分型的有用方法。本研究中描述的动态电阻基因检测系统是监测基因状态的敏感和有用的工具,其通过检测耐药基因突变的出现具有治疗策略的潜力。

著录项

  • 来源
    《Oncology letters》 |2018年第2期|共9页
  • 作者单位

    Shenzhen Peoples Hosp Dept Oncol 1017 Dongmen North Rd Shenzhen 518000 Guangdong Peoples R;

    HaploX Biotechnol Co Ltd 3 Songpingshan Rd Shenzhen 518000 Guangdong Peoples R China;

    HaploX Biotechnol Co Ltd 3 Songpingshan Rd Shenzhen 518000 Guangdong Peoples R China;

    Shenzhen Peoples Hosp Dept Oncol 1017 Dongmen North Rd Shenzhen 518000 Guangdong Peoples R;

    Shenzhen Peoples Hosp Dept Oncol 1017 Dongmen North Rd Shenzhen 518000 Guangdong Peoples R;

    HaploX Biotechnol Co Ltd 3 Songpingshan Rd Shenzhen 518000 Guangdong Peoples R China;

    HaploX Biotechnol Co Ltd 3 Songpingshan Rd Shenzhen 518000 Guangdong Peoples R China;

    HaploX Biotechnol Co Ltd 3 Songpingshan Rd Shenzhen 518000 Guangdong Peoples R China;

    HaploX Biotechnol Co Ltd 3 Songpingshan Rd Shenzhen 518000 Guangdong Peoples R China;

    HaploX Biotechnol Co Ltd 3 Songpingshan Rd Shenzhen 518000 Guangdong Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 肿瘤学;
  • 关键词

    circulating tumor DNA; lung cancer; epithelial growth factor receptor T790M mutation; drug resistance;

    机译:循环肿瘤DNA;肺癌;上皮生长因子受体T790M突变;耐药性;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号